NCT05992545

Brief Summary

The investigators have developed a mobile application named 'DangDang Care' (which conveys the meaning of managing diabetes confidently and consistently through psychological care) designed to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms. The application incorporates a behavioral activation program. Subsequently, the investigators conducted a 12-week randomized controlled trial, enrolling individuals with type 2 diabetes and mild-to-moderate depression, with the assistance of public health centers. The trial aimed to assess the effectiveness and feasibility of the application in promoting consistent diabetes management through added psychological care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
73

participants targeted

Target at P25-P50 for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Jun 2022

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 13, 2022

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 13, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 21, 2023

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

July 23, 2023

Completed
23 days until next milestone

First Posted

Study publicly available on registry

August 15, 2023

Completed
Last Updated

August 18, 2023

Status Verified

August 1, 2023

Enrollment Period

7 months

First QC Date

July 23, 2023

Last Update Submit

August 15, 2023

Conditions

Outcome Measures

Primary Outcomes (8)

  • Changes in Patient Health Questionnaire-9 (PHQ-9) scores

    The PHQ-9 is a 9-item self-report scale developed to assess the presence and severity of depression within the past 2 weeks. It was adapted for use with Korean participants. Respondents rate how often they have been bothered by each problem on a 4-point Likert scale ranging from 0 to 3. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms, and a cutoff score of 10 is used.

    By week 12

  • Changes in Generalized Anxiety Disorder-7 (GAD-7) scores

    The GAD-7 is a brief self-report scale that assesses generalized anxiety disorder, comprising 7 items. Respondents rate the frequency of experiencing symptoms related to generalized anxiety disorder over the past 2 weeks using a 4-point Likert scale ranging from 0 to 3. Total scores range from 0 to 21, with higher scores indicating more severe anxiety. In this study, we used the Korean version of the GAD-7, accessible on the Patient Health Questionnaire website.

    By week 12

  • Changes in Korean version of the Perceived Stress Scale (K-PSS) scores

    The Perceived Stress Scale (PSS), originally developed in 1983, was translated into Korean in 2010 and 2012. The K-PSS consists of 10 items, and respondents rate their responses on a 5-point Likert scale ranging from 0 to 4. The total score ranges from 0 to 40, with higher scores indicating higher perceived stress levels.

    By week 12

  • Changes in Brief Diabetes Distress Screening Instrument (DDS-2) scores

    The DDS-2 is a brief version of the Diabetes Distress Scale, developed in 2008, and was translated into Korean in 2020. It consists of 2 items, and each item assesses the emotional burden of diabetes and the stress of diabetes management and treatment on a 6-point Likert scale ranging from 1 to 6. The total score ranges from 2 to 12, with higher scores indicating higher levels of diabetes-related stress.

    By week 12

  • Changes in European Quality of Life-5 Dimensions 3 Level (EQ-5D-3L) index

    The EQ-5D-3L is a tool developed by the Euro Quality of Life Group to assess health-related quality of life. It comprises a descriptive system with five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Respondents rate their current health state within each domain using three levels. The evaluative system included the EQ-5D-3L index. We employed the EQ-5D-3L index to calculate utility values for health states and evaluate the overall quality of life.

    By week 12

  • Changes in Diabetes Self-Efficacy Scale (DSES) scores

    The DSES, originally developed by the Stanford Patient Education Research Center in 2009, was used in its Korean version translated by Young Sun Yeom in her thesis in 2010. It comprises 8 items, and respondents rate their level of confidence in successfully performing self-care behaviors on a 10-point Likert scale ranging from 1 to 10. Higher scores indicate a higher level of self-efficacy in managing diabetes.

    By week 12

  • Changes in Diabetes Care Profile-Social Support Scale (DCP-SSS) scores

    The Diabetes Care Profile (DCP), developed in 1996, measures psychosocial factors and diabetes treatment. For this study, only the instrumental and emotional support subscales were utilized, and they were translated into Korean in 2007. The scale was modified to fit the study's purpose, resulting in a total of 9 items, excluding 3 items not relevant to the study. Each item was answered on a 5-point Likert scale from 1 to 5, with higher scores indicating higher perceived social support.

    By week 12

  • Changes in Diabetes Self-Management Behaviors for Older Koreans (DSMB-O) scores

    The DSMB-O was developed in 2016 and is based on the self-management standards proposed by the American Association of Diabetes Educators, considering the characteristics of older adults with type 2 diabetes in Korea. The scale consists of a total of 14 questions, with 9 questions answered on a 4-point Likert scale from 0 to 3, and 5 dichotomous questions. The total score ranges from 0 to 30, with higher scores indicating higher levels of diabetes self-care behaviors.

    By week 12

Secondary Outcomes (3)

  • Changes in glycated hemoglobin (%)

    By week 12

  • Changes in fasting plasma glucose levels (mg/dL)

    By week 12

  • Change in lipid profiles, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (mg/dL)

    By week 12

Other Outcomes (8)

  • Persistent changes in Patient Health Questionnaire-9 (PHQ-9) scores

    By week 16

  • Persistent changes in Generalized Anxiety Disorder-7 (GAD-7) scores

    By week 16

  • Persistent changes in Korean version of the Perceived Stress Scale (K-PSS) scores

    By week 16

  • +5 more other outcomes

Study Arms (2)

Mobile application 'DangDang Care' under usual care

EXPERIMENTAL

The intervention group receives 'DangDang Care' alongside usual diabetes care.

Device: Mobile application 'DangDang Care' under usual care

Usual care

NO INTERVENTION

The control group receives only usual diabetes care.

Interventions

The application incorporates a behavioral activation program to provide psychological support and enhance diabetes self-management for people with type 2 diabetes experiencing depressive symptoms, alongside conventional medical therapy. The intervention group receives the mobile application with usual care.

Also known as: DangDang Care
Mobile application 'DangDang Care' under usual care

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 20 to 80 years with type 2 diabetes
  • Individuals belonging to disadvantaged populations, such as medical aid beneficiaries or those classified as low-income groups
  • Mild-to-moderate depressive symptoms, defined as a Patient Health Questionnaire-9 (PHQ-9) score between 5 and 19
  • Capable of reading and understanding Korean and using a mobile application
  • Having a clear understanding of the study's purpose and providing written consent

You may not qualify if:

  • Type 1 diabetes or gestational diabetes
  • Diabetes complications that hindered diabetes self-management
  • Severe depressive symptoms that made app usage and completion of the self-report questionnaire difficult
  • Serious mental illnesses other than depressive symptoms (e.g., schizophrenia and related disorders, bipolar and related disorders, or neurodegenerative disorders)
  • Serious life-threatening medical conditions
  • Physical conditions that impeded mobility
  • A history of traumatic brain injury
  • Unwillingness to complete the questionnaire and provide personal information

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Korea University Anam Hospital

Seoul, 02841, South Korea

Location

Korea University Anam Hospital

Seoul, South Korea

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Depression

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesBehavioral SymptomsBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Associate Professor

Study Record Dates

First Submitted

July 23, 2023

First Posted

August 15, 2023

Study Start

June 13, 2022

Primary Completion

January 13, 2023

Study Completion

July 21, 2023

Last Updated

August 18, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations